ADIPOQ and colorectal carcinoma: The inconsistencies between studies of these metabolic biomarkers and CRC risk may be explained by differences in sample size, study design, study population (e.g., differences in geographic region, sex, age, or risk factor distributions), or biomarker type (e.g., total adiponectin vs high molecular weight adiponectin).